Peptide Cheat Sheet South Africa: What Each Does—and What Not to Pair Blindly

Peptide cheat sheets are popular because they compress a confusing market into a saveable list. The problem begins when mechanism, animal research and influencer experience are presented as if they were clinical instructions. This South African edition separates approved medicine, human clinical evidence, preclinical research and unproven pairing advice.

The local context matters. In 2026, the South African Health Products Regulatory Authority (SAHPRA) warned about unregistered peptide products marketed online and specifically named BPC-157, TB-500, ipamorelin and other compounds. SAHPRA advises patients to use registered products in original packaging, prescribed by registered healthcare professionals and dispensed by licensed pharmacists.¹

Peptide and metabolic compound cheat sheet

Retatrutide and tirzepatide: similar conversation, different status

Both compounds act on incretin pathways, but they should not be treated as interchangeable. Tirzepatide is a registered prescription medicine in South Africa; current SAHPRA-published Mounjaro information includes type 2 diabetes and weight management in defined adult populations. Retatrutide remains an investigational triple-receptor agonist. Its trial results are scientifically important, but they do not establish a public self-treatment protocol.^2–5,16,17

Lilly reported TRIUMPH-1 Phase 3 topline results in May 2026 and further TRIUMPH-2 and TRIUMPH-3 topline results in July 2026.^16,17 These sponsor releases add Phase 3 evidence, but they are not substitutes for complete peer-reviewed reports, independent appraisal or regulatory review. The direct retatrutide-versus-tirzepatide trial, TRIUMPH-5, is active and has not reported results.¹⁹

The original pairing list correctly notices that gastrointestinal symptoms and reduced intake can affect hydration and nutrition. The correction is that these effects are not proof that everyone needs electrolyte products, sublingual B12, TUDCA or a fixed fibre target. The 2026 tirzepatide label warns about gastrointestinal adverse reactions, acute kidney injury related to volume depletion and gallbladder disease; it directs clinical monitoring, not a universal supplement bundle.³

GHK-Cu: promising biology does not prove an injectable stack

GHK-Cu binds copper and is studied in tissue remodelling and aesthetic medicine. A 2026 systematic review found 20 eligible studies, but 18 were preclinical and only two were randomised trials. That is a signal worth following—not a basis for claiming that injectable GHK-Cu plus collagen, vitamin C and zinc is an established protocol.⁶

Vitamin C is required for normal collagen synthesis, and zinc has recognised physiological roles. But more is not automatically better: the US National Institutes of Health notes that high zinc intake can inhibit copper absorption.^7,8 With a copper-binding compound, casually recommending zinc 'for balance' without assessing the person can be especially misleading.

KPV: an anti-inflammatory research signal, not a proven gut protocol

KPV is a three-amino-acid melanocortin-related peptide. Cell and animal studies report anti-inflammatory activity and intestinal uptake mechanisms, but this is not the same as evidence that KPV treats human gut disease or should be paired with probiotics, omega-3 or vitamin D.⁹ Those interventions have separate evidence bases and should not be bundled simply because they share an inflammation narrative.

BPC-157: animal healing research is not clinical proof

BPC-157 is frequently described online as a tissue- and gut-healing peptide. The strongest responsible summary is narrower: preclinical findings are interesting, but human evidence and long-term safety data are inadequate. A systematic review in orthopaedic sports medicine found that nearly all included studies were preclinical.¹⁰

Protein, vitamin C and zinc can matter to normal wound healing when intake is inadequate. They do not validate BPC-157, prove that a marketed vial contains what it claims, or remove the regulatory and injection risks highlighted by SAHPRA.^1,7,8

TB-500: do not collapse thymosin-β4 research into a retail vial

Thymosin-β4 has been studied in wound-healing contexts, including preclinical models and limited clinical development.¹¹ TB-500 is a marketed name used for related peptide products, but a retail research vial is not automatically equivalent to the exact substance, formulation, purity or route studied in a paper. SAHPRA specifically lists TB-500 among unregistered peptides promoted for recovery.¹

Tesamorelin and ipamorelin should not share one evidence label

Tesamorelin is a growth-hormone-releasing factor analogue with a specific FDA indication: reducing excess abdominal fat in adults with HIV and lipodystrophy. Its prescribing information includes contraindications and monitoring considerations, including IGF-1 and glucose effects.¹² That does not make it a general recovery or weight-loss peptide.

Ipamorelin is a different compound and is named in SAHPRA's warning about unregistered peptides.¹ Combining the two under 'TESA / IPA' erases the difference between an indication-specific approved medicine in one jurisdiction and an unregistered secretagogue.

5-Amino-1MQ: a small molecule, not a peptide

5-Amino-1MQ is discussed as an inhibitor of nicotinamide N-methyltransferase (NNMT). Published 5-Amino-1MQ weight research is preclinical, including mouse studies; recent reviews still frame NNMT inhibitor clinical translation as an emerging opportunity rather than an established human fat-loss treatment.^13,18 Claims that it necessarily 'burns through methyl groups' and therefore requires TMG, methylated B vitamins and L-carnitine are mechanistic extrapolations, not a validated clinical protocol.

NAD+: important biology, overextended wellness claims

NAD+ is a coenzyme involved in cellular metabolism; it is not a peptide. A current systematic review describes promising preclinical biology but variable and still-limited human evidence for anti-ageing and wellness outcomes.¹⁴ Evidence about oral NAD precursors, direct NAD administration and different routes should not be merged into one claim.

Magnesium, B12 and folate are essential nutrients, but supplementation is most defensible when intake, medicine use, symptoms or testing identifies a need. NIH guidance also notes that excessive supplemental magnesium can cause adverse effects and interact with medicines.¹⁵

A safer pairing framework

1. Pair the claim with its evidence level: approved indication, human trial, animal study or mechanism only.
2. Pair the product with its regulatory record: check the exact brand, dosage form and registration—not only the ingredient name.
3. Pair treatment with qualified oversight: review diagnoses, medicines, contraindications and monitoring with a registered clinician.
4. Pair nutrition with an identified need: use diet history, symptoms and appropriate tests rather than a universal shopping list.
5. Do not pair unregistered injectables into stacks: combining unknowns compounds uncertainty about identity, sterility, interactions and long-term risk.